Business Context and Reporting Period
This Form 8-K filing by Eterna Therapeutics Inc. (ticker: ERNA) was submitted on August 19, 2024, reporting events occurring on August 16, 2024. The company is incorporated in Delaware and maintains its principal executive offices in Cambridge, MA.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance events and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the scheduling of the 2024 Annual Meeting of Stockholders for September 27, 2024. This date is more than 30 days before or after the one-year anniversary of the 2023 annual meeting, triggering specific notice requirements under the Company's Bylaws.
Guidance, Outlook, and Corporate Actions
- Annual Meeting Date: Set for September 27, 2024.
- Stockholder Notice Deadline: Stockholders must notify the Company of their intention to bring business before the meeting or nominate directors by the close of business on August 29, 2024.
- Proxy Proposal Deadline: Proposals intended for inclusion in the proxy statement under Rule 14a-8 must also be received by the close of business on August 29, 2024.
- Submission Address: Notices and proposals must be directed to the Secretary at 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141.
Key Facts for Investor Verification
- Verify the exact date of the 2024 Annual Meeting (September 27, 2024) against personal calendars for voting or attendance.
- Confirm the August 29, 2024 deadline for submitting stockholder proposals or director nominations to ensure compliance with Bylaws.
- Note that this filing contains no financial updates; investors should refer to the most recent 10-Q or 10-K for financial performance.